Pharmacologic Substance – Page 13

Wave Life Sciences Obesity Biomarker Data Raise Hopes for Future Readouts

1 month ago talkbio0Tagged Activin E :* *, Biological Markers, Body Composition, Clinical Trials, INHBE gene, INLIGHT trial, Obesity, RNA therapeutics, RNA, Small Interfering, Wave Life Sciences, Weight Loss, WVE-007

Wave Life Sciences; WVE-007; obesity; biomarker data; siRNA; Activin E; INHBE gene; RNA therapeutics; clinical trial; body composition; weight loss; INLIGHT trial

Lilly Commits $1.2 Billion to Expand GLP-1 Pill Manufacturing Facility in Puerto Rico

2 months ago talkbio0Tagged Carolina, eli lilly, expansion, Investments, Manufacturing, Oral Medicine, orforglipron, pharmaceutical production, Product containing glucagon-like peptide 1 receptor agonist (product), Puerto Rico, supply chain, United States

Eli Lilly; Puerto Rico; GLP-1 receptor agonist; orforglipron; manufacturing expansion; oral medicines; investment; Carolina; pharmaceutical production; U.S. supply chain

Novo Nordisk Launches Surprise Bid for Metsera, Topping Pfizer Offer; Pfizer Alleges Move May Violate Antitrust Law

2 months ago talkbio0Tagged Acquisition, Antitrust, bidding war, Metsera, Novo Nordisk, Obesity, Pfizer, Twice a day, Unsolicited Adverse Event, Weight-Loss Agents

Novo Nordisk; Metsera; Pfizer; acquisition; bidding war; obesity; antitrust; unsolicited bid; weight-loss drugs

Eli Lilly Blows Past Revenue Benchmarks, Again Raises Full-Year Outlook

2 months ago talkbio0Tagged earnings, eli lilly, exophthalmos producing substance, full-year guidance, Mounjaro, pharmaceutical innovation, Q3, revenue growth, Weight-Loss Agents, Zepbound

Eli Lilly; Q2 2025 earnings; Q3 2025 earnings; Mounjaro; Zepbound; weight-loss drugs; revenue growth; EPS; full-year guidance; pharmaceutical innovation

Roche Signs $1B Licensing Deal with Qyuns Therapeutics for Preclinical COPD Bispecific Antibody

2 months ago talkbio0Tagged Antibodies, Bispecific, biobucks, China, COPD, IL33 protein, human, Preclinical, Qyuns Therapeutics, Respiration Disorders, Roche (company), TSLP gene

Roche; Qyuns Therapeutics; bispecific antibody; COPD; preclinical; TSLP; IL-33; China biotech; biobucks; respiratory disease

FDA Reduces Regulatory Red Tape for Biosimilars

2 months ago talkbio0Tagged approvals, Biosimilars, faster, Financial cost, regulatory changes, United States Food and Drug Administration

FDA; biosimilars; regulatory changes; cost reduction; faster approvals

GSK Trims Pipeline and Upgrades Guidance in Emma Walmsley’s Last Earnings Report

2 months ago talkbio0Tagged dividend, earnings, Emma Walmsley, guidance upgrade, Medical Specialities, operating profit, pipeline reduction, R&D, SmithKline Beecham

GSK; pipeline reduction; earnings; Emma Walmsley; Q3 2025; guidance upgrade; Specialty Medicines; operating profit; dividend; R&D progress

Merck & Co.’s Welireg Notches Wins in Kidney Cancer Combo Studies

2 months ago talkbio0Tagged adjuvant setting, Combined Modality Therapy, Disease-Free Survival, Keytruda, Lenvima, Malignant neoplasm of kidney, Phase 3 trials, Progression-Free Survival, Renal Cell Carcinoma, Welireg

Welireg; kidney cancer; renal cell carcinoma; Keytruda; Lenvima; adjuvant setting; combination therapy; Phase 3 trials; progression-free survival; disease-free survival

Jazz Pharmaceuticals Appoints Dr. Ted Love to Board of Directors

2 months ago talkbio0Tagged Audit Committee, Board appointment, board of directors, Corporate governance, Jazz, Kenneth W. O’Keefe, Retirement, Science, Ted Love

Jazz Pharmaceuticals; Ted Love; Board appointment; Board of Directors; Corporate governance; Audit Committee; Science and Medicine Committee; Kenneth W. O’Keefe retirement

Expert Insights to Navigate Your CGT Challenges: Recent Updates and Strategic Guidance for 2025

2 months ago talkbio0Tagged calcium glucarate, Capital, Challenge, Changing, Cognitive function: planning, gains, Investments, Long-term, minimization, Private Equity, rates, Taxes

capital gains tax; CGT challenges; 2025 tax rates; long-term capital gains; tax planning; tax minimization strategies; Net Investment Income Tax; private equity tax changes